Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
17.24
-0.42 (-2.35%)
At close: Apr 4, 2025, 4:00 PM
17.01
-0.23 (-1.31%)
After-hours: Apr 4, 2025, 7:58 PM EDT

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.

It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.

In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo.

It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation.

Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals logo
Country United States
Founded 1996
IPO Date Nov 29, 2000
Industry Biotechnology
Sector Healthcare
Employees 164
CEO Raul Rodriguez

Contact Details

Address:
611 Gateway Boulevard, Suite 900
South San Francisco, California 94080
United States
Phone 650 624 1100
Website rigel.com

Stock Details

Ticker Symbol RIGL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001034842
CUSIP Number 766559702
ISIN Number US7665597024
Employer ID 94-3248524
SIC Code 2834

Key Executives

Name Position
Raul R. Rodriguez President, Chief Executive Officer and Director
Dean L. Schorno CPA Executive Vice President and Chief Financial Officer
Raymond J. Furey J.D. Executive Vice President, General Counsel and Corporate Secretary
David A. Santos Executive Vice President and Chief Commercial Officer
Julie Patel Senior Vice President of Human Resources
Joseph Lasaga Executive Vice President and Chief Business Officer
Dr. Lisa Rojkjaer M.D. Executive Vice President and Chief Medical Officer
Tarek Sallam Vice President of Marketing

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 10, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Mar 4, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 11, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 144 Filing
Feb 5, 2025 144 Filing
Feb 5, 2025 144 Filing